<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667637</url>
  </required_header>
  <id_info>
    <org_study_id>Y(2020)045</org_study_id>
    <nct_id>NCT04667637</nct_id>
  </id_info>
  <brief_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol</brief_title>
  <official_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol (INSIST-ED): a Prospective, Randomized, Double Blinded, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and efficacy of edaravone dexborneol for the treatment of acute&#xD;
      ischemic stroke patients who received endovascular thrombectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day 90</time_frame>
    <description>Proportion of patients with modified Rankin Score 0 to 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>Day 90</time_frame>
    <description>Proportion of patients with modified Rankin Score 0 to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of modified Rankin Score</measure>
    <time_frame>Day 90</time_frame>
    <description>Distribution of modified Rankin Score after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS)</measure>
    <time_frame>24 hours, 48 hours, and 2 weeks</time_frame>
    <description>the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infarct volume</measure>
    <time_frame>1 week</time_frame>
    <description>infarct volume is determinted by CT or DWI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of intraparenchymal hemorrhage (PH1 and PH2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Proportion of PH1 and PH2 within 48 hours after the treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of death</measure>
    <time_frame>Day 90</time_frame>
    <description>death due to any cause</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke</condition>
  <condition>Endovascular Thrombectomy</condition>
  <arm_group>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injections of 0.9% NaCl BID for 12 ±2days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edaravone dexborneol</intervention_name>
    <description>Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.</description>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
    <other_name>edaravone deborbeol placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 80 years of age;&#xD;
&#xD;
          2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the&#xD;
             anterior circulation and met the criteria of mechanical thrombectomy;&#xD;
&#xD;
          3. Sufficient recanalization within 9 hours of stroke onset;&#xD;
&#xD;
          4. Sufficient recanalization （TICI 2b-3）;&#xD;
&#xD;
          5. Acute ischemic stroke with neurological baseline deficit equivalent to the National&#xD;
             Institute of Health Stroke Scale (NIHSS) ≥ 6 before recanalization treatment;&#xD;
&#xD;
          6. First ever stroke or mRS≤1 after previous disease&#xD;
&#xD;
          7. The availability of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke patients with insufficient recanalization（TICI &lt; 2a）&#xD;
&#xD;
          2. Hemorrhagic transformation (PH2) indicated by NCCT performed after the operation&#xD;
             immediately;&#xD;
&#xD;
          3. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;&#xD;
&#xD;
          4. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （&#xD;
             &lt;100000/mm3）;&#xD;
&#xD;
          5. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          6. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure&#xD;
             over 110 mmHg);&#xD;
&#xD;
          7. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime&#xD;
             less than 3 months;&#xD;
&#xD;
          8. Pregnancy, plan to get pregnant or during lactation;&#xD;
&#xD;
          9. Patients with contraindication or allergic to any ingredient of drugs in our study;&#xD;
&#xD;
         10. Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Sheng T Chen, Ph.D.</last_name>
    <phone>+8613352452086</phone>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zi-Ai Zhao, Ph.D.</last_name>
    <phone>+86 17790998175</phone>
    <email>zhaoziai@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>ShenYang</city>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zi-Ai Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

